Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from HIMS

IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory

Hims stock jumped early Tuesday after the online pharmacy beat expectations, helped by Hims & Hers' weight-loss drug.

Investors Business Daily

Hims & Hers Health Tops Growth 50 List As FDA OKs Cheaper Weight-Loss Drug

Hims stock is near its all time high and a buy point of 25.74.

Investors Business Daily

Hims & Hers Shares Rallied 22% Over Two Days. Why That Move Is Now At Risk.

Hims stock rallied almost 22% over two days on enthusiasm after the FDA said it will allow compounded versions of Lilly's obesity drug.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

Investors Business Daily

Is Hims & Hers Stock a Buy for GLP-1 Upside?

Hims & Hers is a digital health company that is firing on all cylinders, while improving its profit margins at a robust pace.

Barchart

After Doubling in the Past 6 Months, Will Hims & Hers Health Stock Continue Higher?

Telehealth company Hims & Hers is trading near record highs after issuing strong guidance for the full year ahead. With the stock up nearly 145% in the last six months, how much more upside is left for HIMS?

Barchart

Subscription-based care moves beyond peddling birth control and helping with hair loss

Online, direct-to-consumer health care has grown well beyond its roots mostly treating hair loss and acne or selling birth control pills

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

HIMS Associate Professor, earlier suspended on charges of misconduct, appointed District Surgeon in Hassan

Dr. H.C. Lokesh appointed District Surgeon of Sri Chamarajendra Hospital in Hassan after being reinstated in August 2022.

The Hindu

MBBS classes will start in new building of Haveri Institute of Medical Sciences, says Minister Shivanand Patil

Minister for Textiles, Sugarcane Development and Sugar and district-in-charge for Haveri Shivanand Patil announced that the classes of the first year MBBS course would be held at the new building of Haveri Institute of Medical Sciences and Hospital from September.

The Hindu

Fubo’s Maximum Effort Channel Brings Back ALF in Series, Branded Content

Mint Mobile, Fubo, Hims, MNTN, Ring get messages from Paul Fusco’s furry alien

Broadcasting & Cable

Tension at NICU in Hassan Institute of Medical Sciences after stabiliser blast

Tension prevailed in the Neonatal Intensive Care Unit (NICU) of the Hassan Institute of Medical Sciences (HIMS) in Hassan on Sunday when smoke covered the premises broke out following a stabiliser blast.

The Hindu

Insider Trading Picking Up For HIMS, Should You Buy?

Shares of multi-specialty healthcare company Hims & Hers Health (HIMS) gained more than 25% over the past month, with increased insider trading sparking investor interest. However, given its bleak financials, is the stock a buy now? Read more to find out.

StockNews.com

After Plummeting from Covid-Induced Highs, is Now a Good Time to Scoop Up Telehealth Stocks?

Telehealth stocks have declined from the Covid-induced highs and are expected to plunge further due to the nation’s return to normalcy. Moreover, the current macroeconomic headwinds are expected to put added pressure on telehealth companies Teladoc Health (TDOC), American Well (AMWL), Hims & Hers Health (HIMS), iRhythm Technologies (IRTC), and…

StockNews.com

Hims & Hers Health's Return On Capital Employed Overview

According to Benzinga Pro data, during Q1, Hims & Hers Health (NYSE:HIMS) posted sales of $101.31 million. Earnings were up 47.85%, but Hims & Hers Health still reported an overall loss of $16.25 million.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 SPAC Stocks Down More Than 60% Since Going Public

The Federal Reserve's interest rate increases to reduce inflationary pressure, and recession fears, have driven many SPAC stocks to significant price declines of late. The shares of Hims & Hers Health (HIMS), Clover Health Investments (CLOV), and BARK (BARK) have retreated more than 60% since these companies went public via…

HIMS graduation ceremony

Hassan

Benzinga

Earnings Preview For Hims & Hers Health

Hims & Hers Health (NYSE:HIMS) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Hims & Hers Health will report an earnings per share (EPS) of $-0.07.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Hims & Hers Partners With Carbon Health

Hims & Hers Health Inc (NYSE:HIMS) has partnered with healthcare provider Carbon Health to enable access to a broader range of care options through its platform. The partnership will further enable the healthcare company to provide California patients with a better continuum of primary care treatment. The partnership adds the seventh U.S. state…

Benzinga

Hims & Hers Health Expands Skincare Offerings

Hims & Hers Health Inc (NYSE:HIMS) has expanded its skincare collections, including a facial cleanser, moisturizer, daily SPF, spot corrector, and face oil. "We've listened to Hers customers' personal skincare concerns regarding their top skincare recommendations in order to provide the most personalized skincare experience possible, whether one product is used or six,"…

Dynamite News

Delhi government to provide e-Health Cards to Delhiites by next year

Delhi Chief Minister Arvind Kejriwal on Friday instructed the Health Department to distribute e-Health Cards prior to the implementation of the Health Information Management System (HIMS), which is expected to begin from March 2023.

StockNews.com

2 Telemedicine Stocks Wall Street Predicts Will Rally 75% or More

Despite a significant dip in COVID-19 cases worldwide, the demand for telemedicine is expected to remain strong owing to rising chronic diseases and an aging population. The sheer convenience of telemedicine makes it a popular choice for many consumers. So, Wall Street analysts expect telemedicine stocks Hims & Hers Health…

StockNews.com

3 Consumer Defensive Stocks Under $10 Wall Street Predicts Will Rally 30% or More

Rising inflation, supply chain issues, and geopolitical tensions will likely continue to keep the stock market under pressure for the foreseeable future. However, consumer defensive stocks perform relatively well in an inflationary environment. Therefore, Wall Street analysts expect fundamentally sound consumer defensive stocks Coty Inc. (COTY), Hims & Hers (HIMS),…

Benzinga

Hims & Hers Health Stock Gains On Solid Q1, FY22 Outlook

Hims & Hers Health Inc (NYSE:HIMS) reported fourth-quarter FY21 sales growth of 104% year-on-year, to $84.7 million, beating the consensus of $76.79 million. The average order value for the quarter was $74. Q4 2021 ending member subscriptions grew 95% year-over-year to 609,000. The gross profit margin contracted 400 basis points Y/Y to 73%,…

Benzinga

Hims & Hers Health: Q4 Earnings Insights

Hims & Hers Health (NYSE:HIMS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

1 2 3 4 5

People

Arvind Kejriwal

1,344 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.